Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 39Sarcoma 2Gastrointestinal 2Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 19Breast Neoplasms 18Melanoma 2Carcinoma, Non-Small-Cell Lung 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 3toripalimab 1spartalizumab 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Ipilimumab 1Interleukin-2 1Immunotherapy 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × toripalimab × Breast × Clear all
NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Innolake Biopharm

Phase 1/2 Recruiting
200 enrolled
BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡